January 17th, Friday 2014  by unknown
© Elsevier Masson SAS. All rights reserved.
 
Archives of Cardiovascular Diseases Supplements (2014) 6, 1-19 7
Conclusion: after a first acute coronary syndrome, family history,
NSTEMI as first cardiac event and multivessel coronary disease were inde-
pendantly associated with early symptomatic evolution of coronary disease.
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Primary percutaneous coronary intervention of bifurcation lesions
Bassem Rekik, Rania Hammami, Leila Abid, Abdelkader Maalej, Souad
Mallek, Dorra Abid, Mourad Hentati, Samir Kammoun
CHU Hédi Chaker, Service de Cardiologie, Sfax, Tunisie
Introduction: There are little data regarding the outcomes of bifurcation
stenting during the acute phase of stemi, because this group of patient is usu-
ally excluded from trials. 
Methods: In 139 patients who underwent bifurcation stenting, the clinical
characteristics, procedural success, and in-hospital cardiac events were com-
pared retrospectively between the patients with and without stemi. The pci
strategy was at the discretion of the operator.
Results: 41 patients (29, 4%) were hospitalized for stemi and underwent a
bifurcation stenting during a primary pci. Tabagism was significantly more
frequent in patients with stemi. The remaining baseline clinical characteristics
between the 2 groups were similar. The majority of bifurcation lesions (71%)
were seen in the left anterior ascending (lad) artery. The provisional stenting
was more performed in patients with stemi than in the others patients but
without significant difference ( 95,1%vs 83,7%, p=0,06) there were no differ-
ence in the procedural success and the final timi-3 flow, and also in the
1 month, 6 months and 1 year mace between the 2 groups. 
Conclusions: Bifurcation lesions are relatively common in emergent pci
for stemi involving especially the lad. It can be safely treated with a provi-
sional stenting approach, and the immediate and long term outcomes are sim-
ilar to those of stable patients. 
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Percutaneous coronary intervention in Senegal: indications, techniques
and results about 34 cases
Mouhamed Cherif Mboup (1), Massamba Thiam (2)
(1) Hôpital Principal de Dakar, Cardiologie, Dakar, Sénégal – (2) Cli-
nique du Golf, Dakar, Sénégal
Percutaneous coronary intervention with stent  introduced by Sigwart et al
in 1986, remains the treatment of choice for coronary atherosclerotic disease
in its different presentations. However, it is still widely practiced in sub-
Saharan Africa. The aim of this study is to describe the indications, techniques
and results of percutaneous coronary intervention in Senegal.
Methods: We prospectively included all patients who underwent percutaneous
coronary intervention with or without stent implantation between July 2012 and
January 2013. We evaluated the indications of procedures, technical procedures
and results of percutaneous coronary intervention performed in our center.
Results: During the period covered by our work, 34 percutaneous coronary
intervention  were performed in 31 patients. The average age of patients was
60.33±10.8 years. Three patients had underwent coronary angioplasty in
France. The indications of the procedures were dominated by acute coronary
syndromes without ST segment elevation in 19 patients foun. The arterial
acces was radial or femoral respectively in  5 and 29  cases . During the coro-
nary angiography lesions were type B2 / C in 19 patients with TIMI 0 in
9 patients. Procedures were successful in 31 cases with implantation of bare
metal stents  and drug-eluting stents in respectively 30 and 2 cases. A mod-
erate bleeding  was found in one patient.
Conclusion: Percutaneous coronary intervention in low income sub-saha-
rian country is feasible with high success rate and very low complication
despite difficult lesion. Our problems are the availability of a good heart sur-
gery team and the consumables.
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Determinants of improved one-year survival in non-ST-segment eleva-
tion myocardial infarction patients: insights from the French FAST-
MI program over 15 years
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(3) Hôpital Bichat-Claude Bernard, Cardiologie, Paris, France –
(4) Hôpital La Pitié-Salpêtrière , Paris, France – (5) CHU Lille,
Urgences, Lille, France – (6) CHU Henri Mondor, Cardiologie, Créteil,
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tal Saint Antoine, Cardiologie, Paris, France – (9) CHU Rangueil, Tou-
louse, France – (10) CH Le Raincy-Montfermeil, Montfermeil, France
Background. Improved prognosis in non-ST elevation myocardial infarc-
tion (NSTEMI) patients has been mainly attributed to the invasive strategy but
the long-term benefits are more uncertain.
Objective: To assess the determinants of improved one-year survival in
NSTEMI patients.
Methods: Four 1-month French nationwide registries, conducted 5 years
apart (between 1995, 2000, 2005, 2010), including a total of 3,903 with ele-
vated cardiac markers participated NSTEMI patients admitted to intensive
care or coronary care units. We evaluated changes over time in crude 1-year
mortality and determinants of long term survival.
Results: From 1995 to 2010, no major change was observed in patients'
characteristics in NSTEMI population. Early use of antiplatelet agents, β-
blockers, ACE-I and statins increased gradually (P<0.001); use of anticoagu-
lants over then unfractionated heparin (LMWH, bivalirudine or fondaparinux)
increased from 40.8% in 2000 to 78.9% in 2010 (p<0.001); and, percutaneous
coronary intervention (PCI) ≤3 days of admission rose from 7.6% to 48.1%
(P<0.001). One-year death decreased from 20% to 9.8%: adjusted HR for
2010 vs 1995: 0.49 (0.38-0.63). Early PCI (HR 0.70; 95%CI 0.55-0.90), use
of anticoagulants over then unfractionated heparin (HR 0.61; 95%CI 0.50-
0.74) and appropriate early medical therapy (HR 0.56; 95%CI 0.44-0.72) were
predictors of improved survival.
Conclusion: One-year mortality of NSTEMI patients has decreased by a
spectacular 50% in the past 15 years in France. An increased use of invasive
strategy, together with change in type of anticoagulants and appropriate early
medical treatment were the determinants of improved one-year survival.
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Prevalence, clinical profile and 3-year outcomes of acute myocardial
infarction patients with and without obstructive coronary lesions: The
FAST-MI 2005 registry
Romain André (1), Meyer Elbaz (2), Tabassome Simon (3), Etienne Puy-
mirat (4), Pierre-Vladimir Ennezat (5), Patrick Ohlmann (6), Vincent
Probst (7), Bernard Peltier (8), Jean Ferrières (9), Nicolas Danchin (4)
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Objectives: our aim was to describe the clinical profile and to evaluate the
3-year outcome of patients admitted for acute myocardial infarction (AMI)
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according to the presence of obstructive coronary lesions on coronary
angiography (CA).
Methods: within the French FAST-MI 2005 national registry, including
patients with definite AMI and elevated cardiac markers, we analyzed base-
line characteristics and outcomes of patients admitted for STEMI and
NSTEMI according to their coronary status. Obstructive coronary artery
disease (OCAD) was defined by at least one significant stenosis (≥50%) in
a major epicardial coronary vessel. Major events were recorded at hospital
discharge and at 3 years. Finally, long-term net mortality in each group was
assessed by comparing observed mortality rates with standardized French
mortality.
Results: among 2582 participating patients, 6.4% (n=167) had no obstructive
coronary lesion on the first CA (5.21% in STEMI vs. 8.21% in NSTEMI). They
had a lower global cardiovascular risk,  Life threatening symptoms at admission
or in-hospital mortality (1.8% vs. 3% in-hospital deaths for patients without and
with OCAD, respectively, p=0.27) did not differ. By contrast, 3-year prognosis
was better in patients with no OCAD (3-year death rates were 5.9% in patients
without and 13.7% in patients with OCAD, p<0.01). This difference of risk
remain significant after extensive adjustment; HR were 0.31 (p<0.001) for risk
of events and 0.42 (p=0.01) for risk of death at 3-year in patients without
OCAD. Moreover, mortality of ACS without OCAD was comparable with
expected French population of the same age (p=0.32), whereas risk of death was
twice as high in patients with OCAD.
Conclusion: Absence of obstructive coronary lesion was found in 6.4% of
patients admitted for AMI. Moreover, in-hospital mortality was not signifi-
cantly different from that of patients with coronary stenosis. By contrast, their
long-term survival is comparable with the general population.
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Komlavi Yayehd (1), Cecile Ricard (2), Dominique Savary (3), Diane
Lacroix (4), Emanuella Barthes (4), Patrick Joubert (1), Francois-Xavier
Ageron (3), Bernard Audema (1), Gaspard Gheno (3), Loic Belle (2)
(1) Cardiologie, Annecy, France – (2) Hôpital, RENAU, Annecy, France –
(3) SAMU, Annecy, France – (4) Cardiologie, Chambéry, France
Purpose: European guidelines for STEMI encourage healthcare networks
to increase rates of, and decrease delays to, reperfusion. We examined the
effects of training general practitioners (primary care physicians [PCPs])
with equipment for prehospital management of STEMI patients in remote
areas.
Methods: A network for cardiac emergencies was set up in the French
North Alps in 2002 and a permanent registry of STEMI patients has been
kept since. In remote areas (>30 min access for ambulances), 20 local vol-
unteer PCPs were trained and equipped (electrocardiogram machine, fibrino-
lysis kit and automated external defibrillators [AEDs]) to deal with cardiac
emergencies. In this study, when the central call dispatcher receives a tele-
phone call from a patient reporting chest pain with a high probability of
STEMI in such an area, he sends a mobile intensive care unit (MICU) with
a doctor on board and asks the local PCP, if one is available, to manage the
patient while awaiting arrival of the MICU. Patients were taken by MICU to
the interventional cardiology hospital if the diagnosis of STEMI was
confirmed. We report on patients who received care from a PCP before
arrival of the MICU.
Results: Of the 930 patients included in the STEMI registry, 184 presented
in an isolated area of whom 144 were in an area with a participating PCP;
56 patients were treated by a PCP before MICU arrival. Thirty of the PCP-
treated patients underwent thrombolysis and 8 patients with ventricular tachy-
cardia/fibrillation were shocked with an AED before MICU arrival. Median
time from onset of chest pain to thrombolysis were shorter when the patient
was managed by the PCP versus MICU alone in a remote area: 105 (75-155)
min vs 120 (75-182) min, respectively (p=0.84). A diagnosis of STEMI
without contraindication to thrombolysis was confirmed in the hospital in 29/
30 patients treated as such by the PCP (one Takotsubo syndrome).
Conclusions: These data suggest that PCP care of STEMI patients located
in isolated areas is safe and efficient, with high rates of resuscitation and
thrombolysis. The rate of GP intervention in our network needs to be
increased in order to optimize management of such patients.
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SYNTAX score is associated with in-hospital mortality as assessed by
GRACE risk score in patients with acute myocardial infarction
Aurélie Gudjoncik (1), Sophie Richet (1), Abdelghani Derrou (1), Joelle
Hamblin (1), Jack Ravisy (2), Philippe Buffet (1), Laurent Mock (2), Phi-
lippe Brunel (2), Damien Brunet (2), Marianne Zeller (3), Yves Cottin (1)
(1) CHU Bocage, Cardiologie, Dijon, France – (2) Clinique de Fontaine,
Cardiologie, Fontaine Les Dijon, France – (3) INSERM U866, LPPCM,
Faculté de Médecine, Dijon, France
Background: Current guidelines for the management of patients with
acute myocardial infarction (AMI) recommend the GRACE score for risk
stratification with assessment of admission variables. The syntax score (SS) is
a comprehensive angiographic scoring system that is derived entirely from the
coronary anatomy and lesion characteristics. We investigated the relationship
between severity of coronary artery disease (CAD) assessed with SYNTAX
Score (SS) and GRACE Score (GS) in patients with AMI.
Patients and Methods: From the obseRvatoire des Infarctus de Côte d’Or
(RICO) survey, 614 consecutive patients hospitalized for an AMI from
1st march 2011 to 30 august 2012 and who underwent coronary angiography
were included. Patients were analyzed into 3 tertiles of risk based on GS.
Results: The tertiles of risk were defined as low (n=205)(GS<133), inter-
mediate (n=204)(GS:133-165), and high risk (n=205)(GS: >165). Age and co-
morbidities increase gradually with increased GS risk. Also, the number of
diseased vessels on coronary angiography increased across the tertiles
(p<0.001). In-hospital mortality increased from the low to the highest tertile
(0.5%, 2.0% and 11.8%, p<0.001). Patients at high risk had significantly
higher SS values compared with the intermediate and low GS risk (median
(IQR) SS: 13(6-20) vs 9(4-15) vs 7(3-12), respectively, p<0.001). Moreover,
SS was strongly correlated with GS (r=+0.254, p<0.001), and remained signif-
icant in patients with multivessel disease. By logistic regression analysis, both
GS and SS score are significant correlate of hospital mortality
(OR(95%CI)1.04(1.02-1.05), p<0.001 and OR(95%CI) 1.11(1.07-1.15)).
Conclusion: Although SS and GS don’t share any common items, they are
strongly associated for prognostic information. Both scores allow for an accu-
rate personalized assessment of patient risk.
028
Is one measurement of copeptin plus high-sensitivity cardiac tropo-
nin T assays at admission sufficient to exclude non-ST-segment eleva-
tion myocardial infarction in the emergency department?
Komlavi Yayehd (1), Eulophe Dubie (2), Emilie Bohyn (3), Christophe
Lebrun (3), Jerome Jund (4), Gaspard Beaune (3), Mathieu Chacornac (1),
Patrick Lessage (2), Dominique Savary (4), Loic Belle (4)
(1) Cardiologie, Annecy, France – (2) SAMU Chambéry, Chambéry,
France – (3) SAMU, Annecy, France – (4) Hôpital, RENAU, Annecy, France
Purpose: Guidelines recommend repeating measurement of cardiac tro-
ponin 6-12 h after admission, or high-sensitivity troponin T (hs-TnT) 3 h after
admission, to establish a diagnosis in patients with suspected non-ST-segment
elevation myocardial infarction (NSTEMI). We sought to test whether the
addition of copeptin, an indirect marker for argininvasopressin, adds predic-
tive information to cardiac troponin in the early evaluation of these patients,
with a view to minimizing length of stay in the emergency department.
Methods: Consecutive adults (≥18 y) admitted for chest pain of <6 h duration
and a suspected NSTEMI to the emergency departments of two hospitals were
enrolled in this prospective observational study. Patients with ST elevation myo-
cardial infarction were excluded. Blood samples were drawn to test hs-TnT and
copeptin at admission, and troponin I (TnI) at admission and 12 h later. The fol-
lowing concentrations were considered to be negative: hs-TnT <14 pg/mL;
copeptin <14 pmol/L; and TnI <0.03 ng/L. The results for copeptin in addition to
hs-TnT at admission, and TnI at admission and 12 h later, were compared.
Results: Of the 245 patients included (mean age 63 [25-91] y; 135 men),
109 were negative for both hs-TnT and copeptin (negative group) and 136
were positive for one or both assays (positive group). Of the patients in the
negative group, 105 (96%) were negative for TnI at admission and at 12 h; the
other 4 patients had a positive second TnI result, and were diagnosed with
© Elsevier Masson SAS. All rights reserved.
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NSTEMI. In the positive group, one or both TnI measures were positive in
37 (27%) of the patients. The final diagnosis was NSTEMI in 39 patients and
unstable angina in 11 patients. The negative predictive value of copeptin in
addition to hs-TnT to predict TnI results was low, at 96%.
Conclusion: The diagnosis of NSTEMI cannot be ruled out in patients
with negative results for both hs-TnT and copeptin at admission. Repeating
the measurement of cardiac troponin (6-12 h for TnI; 3 h for hs-TnT) after
admission remains the gold standard.
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Fragmented QRS in patients with STEMI undergoing PCI: relation to
ST segment resolution and determinism
A sub analysis of the MISTRAL study
Céline Zerbib, Patrick Ohlmann, Olivier Morel, Bogdan Radulescu,
Sébastien Hess, Hélène Kremer, Ulun Crimizade
NHC, Strasbourg, France
Purpose: Fragmentation of QRS is a recognized markor of myocardial scar
and is associated with prognosis. ST segment resolution (STR) in ST segment
elevation myocardial infarction (STEMI) is a landmark of tissue reperfusion.
We thought to investigate the relationship between fQRS and STR in STEMI
patients undergoing primary percutaneous intervention and to determine the
predictors of fQRS.
Methods: The ECG of 256 patients included in a multicentric STEMI-PCI
study were analyzed. fQRS and ST- segment resolution were evaluated at the
time of arrival of mobile intensive care unit and at H1 post-PCI. Major clinical
cardiac events (mortality, re-infarction and target vessel revascularization)
were assessed at 30 days and 6 months.
Results: FQRS was present in 33 patients (13.6%) on ECG-MICU and 30
(12%) on ECG-H1. The presence of fQRS on MICUņ or H1ņECG was not asso-
ciated either with STR or with clinical outcome. In multivariate analysis, the inde-
pendent predictors of fQRS on ECG-MICU were female gender (OR 2.37,
[CI=1.02-5.49], p=0.04 ), cardiac troponin Ic level at H72 (OR 1.03, [CI=1.00-
1.06], p=0.01), TIMI 0-1 flow rate pre-PCI (OR 1.96, [CI 1.27-2.96], p=0.002)
and inferior location of STEMI (OR 2.39, [CI=1.02-5.57], p=0.04). Patients with
fQRS pre-PCI presented a percent necrosed mass significantly more important on
cardiac MRI than patients without fQRS (33% vs 17%; p=0.04).
Conclusion: The presence of fQRS at the time of presentation or 1 hour
after PCI was not associated with ST- segment regression. FQRS was related
to enzymatic infarct size, inferior location, low TIMI flow rate.
Keywords: fragmented QRS, ST segment resolution, STEMI
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Patients with non-obstructive coronary artery disease and acute coronary
syndrome: characteristics and prognosis according to the CMR findings
Frédéric Moulin (1), Zied Frikha (1), Thibaud Vaugrenard (1), Pierre-
Yves Marie (2), Etienne Aliot (1), Michael Angioi (1), Olivier Huttin (1)
(1) CHU Brabois, Département de Cardiologie, Vandoeuvre Les Nancy,
France – (2) CHU Brabois, Service de Médecine Nucléaire, Vandoeuvre
Les Nancy, France
Introduction: Clinical features and prognosis of patients with Non-ST
Elevation Myocardial Infarction (NSTEMI) and no significant coronary artery
disease (CAD) with approved ischemic cause in Cardiovascular Magnetic
Resonance (CMR) was not well studied.
Objectives: The aim of our study is to compare the clinical profile, demo-
graphic characteristics and outcomes of patients with or without approved
ischemic cause on CMR.
Methods: A retrospective monocentric study enrolling all subsequent patients
hospitalised for NSTEMI without significant CAD (stenosis <50%), between
January 2004 and January 2010. All patients underwent CMR and were divided
up into two groups, depending on CMR findings. In the first group, 43 patients
with confirmed myocardial infarction and group 2 consisted of 96 non-ischemic
patients (confirmed acute myocarditis or normal/non-contributory CMR).
Results: Baseline clinical, electrocardiographic and echographic characteristics
were similar between the 2 groups except a significant higher prevalence of hyper-
tension in group 1 (32.6% vs 10.4%; p<0.005) and patients with approved isch-
emic cause were significantly older than group 2 (51.9±14.2 vs 42.2±16.1;
p<0.001). The GRACE score at admission was significantly higher in ischemic
group (103.4±34.7 vs 84.9±22.8; p<0.05). In contrast, CRP level was significantly
lower in group 1 as compared to non-ischemic group (5.8±7.1 vs 28.7±37.1 mg/l;
p<0.0001). After a mean follow-up of 55 months, death rate was higher in the
group 1 without being statistically significant (p=0.09). Also, the composite
MACE seemed to be higher in the ischemic group (12.2% vs 3.2%; p=ns).
Conclusion: Our study demonstrates that among NSTEMI patients and no
significant CAD undergoing CMR, an approved ischemic cause is more common
in old patients having a high GRACE score at admission. The prognosis in this
group seemed to be worse when compared to the non-ischemic patients.
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Medical treatment of patients with non-significant stenosis and bor-
derline fractional flow reserve is safe
Florence Verdier-Watts (1), Thibault Perret (2), Jean-Raymond Caignault
(2), Olivier Dubreuil (2), Sylvain Ranc (2), Marie Pirel (2), Bernard Ritz
(2), Delphine Mioulet (1), Vincent Griffet (1)
(1) Hôpital Desgenettes, Lyon, France – (2) Hôpital Saint-Luc-Saint-
Joseph, Lyon, France
Objectives: To assess the clinical outcome of intermediate coronary ste-
nosis in case of borderline fractional flow reserve (between 0,81 and 0,85)
after deferral of revascularization
Background: Medical treatment of patients with nonsignificant stenosis
(FFR>0,80) is associated with a favorable clinical outcome for mean FFR
value >0,85 (FAME study)
Methods: Patients with intermediate coronary stenosis and measurement of
FFR>0,80 and ≤0,85 were included. The rate of cardiac death, myocardial infarc-
tion, coronary revascularization and angina were evaluated during the follow-up
Results: 42 intermediate chronic stenosis (%DS 61±9%) in 40 patients with a
mean FFR value of 0,83±0,01 were deferred of revascularization. At a mean
follow-up of 11±9 months there was no death and no myocardial infarction, the
rate of revascularization was 4,8%, and 81% of patients were free from angina
Conclusion: Medical treatment of patients with nonsignificant stenosis in
the borderline FFR range (0,81≤FFR≤0,85) is associated with a favorable clin-
ical outcome at medium term
Key Words: Fractional Flow Reserve, FFR borderline 
Figure – FFR range (our study in black, FAME study in red)
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What are the limiting factors of CMR to identify the cause in patients
presenting with non-ST-segment elevation myocardial infarction and
no significant lesions in coronary arteries 
Frédéric Moulin (1), Zied Frikha (1), Thibaud Vaugrenard (1), Pierre-
Yves Marie (2), Etienne Aliot (1), Michael Angioi (1), Olivier Huttin (1)
(1) CHU Brabois, Département de Cardiologie, Vandoeuvre Les Nancy,
France – (2) CHU Brabois, Service de Médecine Nucléaire, Vandoeuvre
Les Nancy, France
Introduction: Etiological diagnosis of patients presenting with Non-ST-
segment elevation myocardial infarction (NSTEMI) with no significant lesions
in coronary arteries is a clinical challenge. Cardiovascular magnetic resonance
(CMR) has the potential to clarify the underlying pathology in this group of
patients. 
Objectives: The objective of this study was to investigate the diagnostic
value and the limiting factors of CMR to identify the underlying cause of
NSTEMI patients without significant lesions in coronary arteries.
Methods: A retrospective monocentric study enrolling all subsequent
patients (n=139) hospitalised for NSTEMI without significant lesions in coro-
nary arteries (stenosis <50%), between January 2004 and January 2010. All
patients underwent CMR with sequences dedicated for the evaluation of myo-
cardial delayed enhancement. CMR scans were analysed independently by
two experienced interpreters.
Results: CMR provided etiologic diagnosis in 117 patients (84.2%). In the
remaining patients, there was no detectable myocardial infarction or inflam-
mation and no additional new diagnosis were made. There was 100% concor-
dance of diagnosis between the two observers. Acute myocarditis was the
most common diagnosis, wich was present in 74 patients (53.2%). Myocardial
infarction was found in 43 patients (30.9%). The limiting factors of CMR to
identify the underlying cause were: female sex (63.6% vs 30.8%; p<0.005)
and a low level of troponine (0.8±1.0 ng/ml vs 7.1±7.7 ng/ml; p<0.0001).
Conclusion: Our study demonstrates the interesting role of CMR to iden-
tify the underlying cause of NSTEMI patients without significant lesions in
coronary arteries. Female sex and low level of troponine were associated with
non-contributory CMR.
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Outcome of patients receiving a triple antithrombotic therapy after
acute myocardial infarction
Fathia Mghaieth Zghal (1), Sinda Hannachi (1), Hatem Aloui (1),
N Tabedi (1), B Rekik (1), Ayari Jihen (1), Mohsen Jamaa (1), Sihem
Mbarki (1), S Boudiche (1), Sami Mourali (2), Abdeljalil Farhati (2),
N Larbi (1), Rachid Mechmèche (2)
(1) Hôpital la Rabta, Cardiologie, Tunis, Tunisie – (2) Hôpital la Rabta,
Tunis, Tunisie
Aim: To characterize outcome in patients receiving a triple antithrombotic
therapy (TAT) after myocardial infarction.
Methods: A cohort of 665 patients (59.3±12 yrs, 83% males) with ST ele-
vation (STEMI) or non ST elevation (NSTEMI) myocardial infarction was
prospectively enrolled. All patients were prescribed a double antiplatelet
therapy (DAPT) combining aspirin and clopidogrel. Patients who could not
receive a DAPT were excluded; n=13. Patients with an indication for long
term anticoagulation (group1) received a TAT for variable durations and
target international normalized ratio ranges (INRt). Factors related to outcome
were determined. 
Results: Sixty patients (9%) received a TAT. Main indications were: atrial
fibrillation (AF); 55%, mechanical valves;13.3%, left ventricular (LV)
thrombus; 33.3%, low LV ejection fraction (EF) with contrast; 25% and
thromboembolic disease; 6.7%. INRt was >3 in 13.3% cases. In-hospital
major cardiovascular events (MACE) (death, réinfarction, shock and stroke)
were more frequent in group1; 16.7% vs 2.6%, p<0.001 but not hemorrhages
5% vs 2.8%, p=0.34. After mean follow of 16.1±11.8 months, survival curves
showed a poorer outcome in group1 with a greater incidence of MACE (death,
re-infarction, stent thrombosis, cardiac insufficiency and stroke) and major
hemorrhages (figure1). Conditions requiring a TAT were the more potent risk
factor of MACE in this population; RR=2.9, CI [1.8-4.6], p<0.001. Other
independent risk factors were hypertension; RR=1.6, CI [1-2.3], stroke
RR=2.5, CI [1.4-4.7], NSTEMI; RR=1.5, CI [1-2.2] and LVEF<0.4; RR=2,
CI [1.3-3] while the INRt was not a significant predictor of outcome.
Conclusion: in our population characterized by a high prevalence of val-
vular diseases, 9% of patients received TAT after myocardial infarction. This
group is characterized by a severe both bleeding and cardiovascular outcome.
It needs close follow up. Optimal antithrombotic therapy remains to be deter-
mined in this population.
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The STIB score: a simple clinical test to predict clopidogrel resistance
Delphine Legrand (1), Emanuele Barbato (2), Patrick Chenu (3), Julien
Magne (1), Victor Legrand (1), Mathias Vrolix (4), William Wijns (2) on
behalf of STIB investigators
(1) CHU Liège, Cardiologie, Liège, Belgique – (2) Olz Aalst, Cardiologie,
Aalst, Belgique – (3) CHU Mont Godinne, Cardiologie, Yvoir, Belgique –
(4) St Jan Ziekenhuis, Cardiologie, Genk, Belgique
Background: High Platelet Reactivity (HPR) to clopidogrel is associated
with an increased risk of ischemic complications during and after coronary
interventions and concerns up to 50% of patients undergoing PCI.
Aim of the study: Identify patients with HPR to clopidogrel using bedside
clinical information.
Methods: Data on platelet reactivity using the VerifyNow® point of care
assay were obtained in 844 patients undergoing PCI for stable coronary artery
disease 12 to 24 hours after a 600mg loading dose of clopidogrel was given.
Demographic, clinical and baseline routine biological tests were obtained and
compared with P2Y12 Reaction Units (PRU). Patients with PRU>230 (HPR)
were considered as non responders to clopidogrel.
Results: HPR was observed in 424/844 pts. Age, weight, body mass index
(BMI), HPR to aspirine, diabetes, renal failure (MDRD<60 ml/min), hemo-
globin (Hb), hematocrit, fibrinogen, glycemia and glycated hemoglobin were
associated with HPR to clopidogrel. In multivariate analysis, only Hb
(OR: 0.77), BMI (OR: 1.06) and diabetes (OR: 1.62) emerged as independent
risk factors. Hb<13.9 g/dl, BMI >28 Kg/m² and presence of diabetes were
equally associated to predict HPR and can be added to derive a simple score
to predict clopidogrel resistance (figure 1)
Although 38.5% of patients without a single clinical predictor still have
HPR, 2/3 patients with 2 or 3 risk factors are resistant to clopidogrel.
Conclusions: STIB HPR score allows identification of patients with a high
probability of resistance to clopidogrel based on diabetes, Hb<13.9 g/dl and
BMI>28 kg/m². This bedside clinical test can be useful to identify patients in
whom another P2Y12 inhibitor should be recommended before and after PCI.
035
Impact on long-term prognosis of dual antiplatelet therapy duration
in patients with long lesion stenting over 30 mm
Aurélie Manchuelle (1), Cedric Delhaye (2), Arnaud Sudre (2), Etienne
Puymirat (3), Laurent Bonello (4), Guillaume Schurtz (1), Jean Marc
Lablanche (2), Christophe Bauters (1), Gilles Lemesle (2)
(1) CHRU Lille, Hôpital Cardiologique, USIC et Centre Hémodynamique,
Lille, France – (2) CHRU Lille, Hôpital Cardiologique, Centre Hemodyna-
mique, Lille, France – (3) Hôpital Européen Georges Pompidou (HEGP),
Cardiologie, Paris, France – (4) Hôpital Nord, Marseille, France
Background: Optimal duration of dual antiplatelet therapy (DAPT) after
stenting is a critical question especially in long lesions that are a well-known
predictor for stent thrombosis (ST).
Methods: Altogether, 573 consecutive patients treated with long stents
>30mm were retrospectively included between 2007 and 2011. Patients were
evaluated for rates of death, major cardiovascular and cerebral events
(MACCE), ST and bleedings. The median time of follow-up was 30 months.
Results: The mean duration of DAPT was 24 months. When DAPT is ana-
lyzed as a continuous variable, long duration of DAPT was associated with lower
rates of death (p<0,001; HR=0,88 per additional month of treatment), MACCE
(p=0,035; HR=0,98), and ST (p=0,002; HR=0,98). There was no increase in
bleedings. As shown by Figure 1 and when DAPT is analyzed as a categorical
variable (threshold at 24 months), among patients alive at 24 months (n=493),
patients who had stopped DAPT before 24 months had higher mortality rate
(11,2%) as compared to patients who stopped after (6,7%) and to those who never
stopped until death or the end of follow-up (0%).
Conclusion: For patients with long stents >30mm, long duration of DAPT
is associated with lower risks of death, MACCE and ST (figure next page).
036
Risk factors associated with myocardial damage induced by PCI
Thibaut Petroni (1), Valérie Duchatelle (2), Philippe L'Allier (3), Jean-
François Tanguay (4), Stephen Robb (5), Jessica Mann (5), Dominique
Johnson (6), Daniel Cournoyer (6), Marie-Claude Guertin (6), Scott
Wright (7), Jean-Claude Tardif (8)
(1) Hôpital La Pitié-Salpêtrière, Cardiologie, Paris, France – (2) Hôpital
Bichat-Claude Bernard, Cardiologie, Paris, France – (3) Institut de Car-
diologie de Montréal, Hémodynamie, Montréal, Canada – (4) Institut de
Cardiologie de Montréal, Unité coronarienne, Montréal, Canada –
(5) F Hoffmann – La Roche, Cardiologie et Métabolisme, Basel, Suisse –
(6) Institut de Cardiologie de Montréal, Centre de Coordination MHICC,
Montréal, Canada – (7) Mayo Clinic, Cardiovascular Diseases, Roches-
ter, Etats-Unis – (8) Institut de Cardiologie de Montréal, Cardiologie,
Montréal, Canada
Background: Percutaneous coronary intervention (PCI) may cause peri-
procedural myocardial damage (MD).
Purpose: The purpose of this study was to identify factors associated with
MD related to PCI in patients presenting for acute coronary syndrome (ACS).
Methods: The Select-ACS study aimed to evaluate the administration of a
P-selectin antibody to reduce MD resulting from PCI in patients hospitalized
for ACS without ST-segment elevation. We included all the patients of the
placebo group in this analysis. MD related to PCI was quantified by the
plasma concentration of the MB fraction of creatinine kinase and cardiac tro-
ponin I 24h after the procedure. The potential risk factors associated with MD
were evaluated in univariate analysis. The results are reported with the lowest
p-value between the two cardiac biomarkers.
Results: PCI was performed in 115 patients referred for ACS without
ST segment elevation and included in the placebo group of the Select-ACS
study. None of the cardiovascular risk factors seemed to be associated with
post-angioplasty MD, including diabetes mellitus (p=0,59). Considering
angiographic characteristics, no correlation was found between MD and
the coronary artery treated (p ranging from 0,34 to 0,77) or the presence
of a bifurcation lesion (p=0,06). MD was not linked to the presence of a
visible intracoronary thrombus (p=0,54) and did not seem to be reduced by
the administration of glycoprotein IIbIIIa inhibitors (p=0,66). Regarding
the PCI characteristics, the duration of the procedure (p=0,08) and the type
of stent implanted (drug-eluting stent versus bare-metal stent, p=0,11) did
not show a clear impact on the incidence of MD. However, total stent
length (p=0,004), stent diameter (p=0,004) and the number of stents
implanted (p=0,007) were associated with the occurrence of PCI-related
MD.
Conclusion: This study suggests that myocardial damage related to PCI is
associated with the number of stents, increasing total stent length and larger
stent diameter.
Figure 1 – STIB Score to predict clopidogrel resistance
© Elsevier Masson SAS. All rights reserved.
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Evaluation of reendothelialization and thrombus formation with Poly-
zene-F nanocoated Cobra stent. In vivo results of stented rabbit iliac
arteries
Luc Maillard (1), Delphine Corsaux (2), Alexandre Altié (3), Alexandre
Ung (2), Joel Courageot (3), Emmanuel Teiger (4), Eric Van Belle (2)
(1) Clinique Axium, Cardiologie, Aix En Provence, France – (2) CHU
Lille, Lille, France – (3) CHU Marseille, Marseille, France – (4) CHU
Créteil, Paris, France
Background: The CeloNova COBRA PzF™ Coronary Stent is a new
stent design, balloon expandable cobalt chromium alloy coronary stent that
is pre-mounted on a custom rapid exchange balloon delivery catheter. The
alloy stent is surface treated with a nano-layer Polyzene®-F (PzF) [Poly-
bis(trifluoroethoxy) phosphazene]. Polyzene-F is an inorganic polymer
with a high molecular weight. In vitro and in vivo studies have indicated
that the nano-layer surface treatment is a nonthrombogenic and has anti-
inflammatory and pro-endothelialization properties that help prevent tissue
reactions.
Materiel and method: Following stent implantation, 32 external iliac
rabbit arteries were harvested at 7 days for electron microscopy analysis, half
cylinder for thrombus area formation and the other half cylinder for reendo-
thelialization. 
Results: 2 occluded stents were observed in control COBRA BMS
group (2/17, 11.76%)  versus  0  (0/15, 0%)  in the COBRA PzF group,
p=0.48 , NS, exact Fisher test. Almost a complete coverage of endothelial
cells was observed in both group. 99.86 +/- 0.09 % in the COBRA BMS
group versus 99.54 +/- 0.25% in the COBRA PzF group, (p =0.22, NS),
non paired t tested. The only defects of reendothelialization were observed
on pieces of struts of stents in front of take off of  large side branches in
both group. No thrombus area was observed in both group at day 7 ( 0%
versus 0% ).
Conclusion: While non significant, there is a reduction of stent occlusion
in the COBRA PzF group, with a complete and rapid reendothelialization at
day 7 that compare favorably with previous and historical data on the same
model. These data will serve as impetus to perform clinical study with reduc-
tion of DAPT.
038
Non-ST-elevation myocardial infarction in patients with no significant
lesions in coronary arteries: the experience of the cardiology departe-
ment of Nancy, France
Frédéric Moulin, Zied Frikha, Thibaud Vaugrenard, Simon Lemoine,
Etienne Aliot, Michael Angioi
CHU Brabois, Département de Cardiologie, Vandoeuvre Les Nancy, France
Introduction: Non-ST-elevation myocardial infarction (NSTEMI) and no
significant coronary artery disease (CAD) is a well-known condition but it still
a challenge in medical practice because of the lack of evidence-based medical
data on it clinical features and it prognosis.
Objectives: The purpose of the study is to describe our experience with
patients who had a NSTEMI without significant lesions in coronary arteries.
The demographic and clinical characteristics and outcomes of these patients
are discussed.
Methods: A retrospective monocentric study enrolling all subsequent
patients hospitalised for NSTEMI, between January 2004 and January 2010.
Only patients without significant lesions in coronary arteries (stenosis < 50%)
were included.
Results: Patients selected according to predefined angiographic criteria com-
prised 5.5% (n=139) of all patients hospitalised for NSTEMI (n=2510). These
patients were characterized by their young age (mean age = 45±16.1 years),
male dominance (64%). Smoking was the most common risk factor for coronary
heart disease in this group (41.7%). The prevalence of the others cardiovascular
risk factors was low: 21.6% had dyslipidemia, 22.3% had a family history of
CAD, 17.3% had hypertension and 2.3% were diabetic. ECG at admission was
normal in 69.1% of cases. Negative T waves were the most described electric
abnormalities (18.7% of cases). The peak troponin level was 6.1±7.4 ng/ml. The
mean LVEF was 57.9±6.5%. After a mean follow-up of 55 months, overall mor-
tality, MACE and stroke were noted respectively in 1.4%, 5.9% and 0.7% of
cases. On univariate analysis, only an approved ischemic cause on cardiac
magnetic resonance was predictive of mortality.
Conclusion: Our study demonstrates that NSTEMI patients with absence
of obstructive CAD are young patients having a low prevalence of risk factors
for coronary heart disease. The prognosis in this group is favourable.
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Abstract 035 – Figure – Mortality according to the duration of DAPT
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Type 1 diabetes mellitus and acute myocardial infarction
Sophie Richet (1), Aurélie Gudjoncik (1), Abdelghani Derrou (1), Claude
Touzery (1), Maud Maza (1), Carole Richard (2), Luc Lorgis (1), Yves
Cottin (1), Marianne Zeller (3)
(1) CHU Bocage, Cardiologie, Dijon, France – (2) CHU, REA SIC, Dijon,
France – (3) INSERM U866, LPPCM, Faculté de Médecine, Dijon,
France
Background: The increased risk of premature heart disease in T1DM is
poorly understood. This study analyzed characteristics, and prognosis of
patients with T1DM and acute Myocardial Infarction (MI).
Methods: Patient population was included from the French regional RICO,
a large regional database of acute MI. 4 cohorts were built: each T1DM
patient was matched with 4 non DM patients, 2 T2DM patients without
chronic insulin therapy, and 1 T2DM with chronic insulin therapy.
Results: Among 12155 MI patients included in RICO database,
46 patients were identified as T1DM, with a prevalence of 1.6% among the
diabetic patients. In T1DM group, age of first AMI was younger compared
to the other groups: 53±12 years. Rate of hypertension was increased (61%
vs 33%), BMI was lower (25 vs 27 kg/m²), and co-morbidities including
renal and heart failure, PAD, stroke, and CABG were markedly higher
when compared with no DM. GRACE risk score was elevated in T1DM,
when compared with non DM group (136 vs 120). NT pro BNP and HDL
cholesterol were increased whereas triglycerides, total and LDL choles-
terol, and creatinine clearance were lower in T1DM compared with the
other groups. At follow-up of T1DM group (30±6 months), HbA1c were
high and creatinine clearance low. Retinopathy and nephropathy were very
common in T1DM.
Conclusion: The present study suggests that T1DM is a severe condition
in patients with acute MI. The major co-morbiditiy in T1DM is chronic renal
failure, which is associated with worse prognosis.
040
Dobutamine stress echocardiogaphy at hypertensive patients (Moroccan
experience) 
Zineb El Honsali, Meryem Alj, Faima Waderrahmane
CHU Ibn Rochd, Casablanca, Maroc
Objective: this study attempted to determine the safety and accuracy of
dobutamine atropine stress echocardiography for detection of the coronary
heart disease in essential hypertensive patients with chest pain (systolique
blood pressure: 160.0± 3.8; diastolic blood pressure: 100.6±2.1). 
Design and methods: 200 essential hypertensive patients underwent
dobutamine atropine stress echocardiography. Echocardiograms were obtained
at baseline and at low (10 μg/Kg body weit per minute) to pick (40 μg/Kg)
dosis of dobutamine adding atropine if necessary. Rest and stress left ventric-
ular wall motion scores were derived from analyses of regional wall motion.
All patients underwent coronary angiography. 
Results: Dobutamine infusion termined after the achievement of target
heart rate of maximum protocol in 184 patients. Wall motion abnormalities
were registered in 16 patients .No patients had prolonged ischemia or sus-
tained arrhythmia. At coronary angiograph 162 patients had significant
coronary heart disease (>70% diameter stenosis).The use of the change in
global wall motion score index from low to pick dose resulted in a sensi-
tivity of 93% for dobutamine atropine stress echocardiography and speci-
ficity of 100% for detection of coronary artery disease. The sensitivity for
detection of triple, double and single vessel disease was 100%, 98% and
75% respectively.  
Conclusion: This method is even better in providing high specificity
and sensitivity for the detection of the coronary artery disease in patients
with essential hypertensive than in other groups of patients with lower side
effects. 
041
Glycoprotein IIb/IIIa inhibitors in acute ST-segment elevation myo-
cardial infarction: audit of clinical practice
Pascale Cuny (1), Sophia Benmiloud (1), Juliette Oliary (1), Patrick Henry (2),
Stéphane Manzo-Silberman (2)
(1) CHU  Lariboisière, Pharmacie, Paris, France – (2) CHU Lariboisière,
Cardiologie, Paris, France
Pharmacotherapy in acute ST-Segment elevation myocardial infarction
(STEMI) patients appears to be always more essential in the management of
the acute phase. Guidelines highlights the immediate administration of dual
antiplatelet therapy and anti thrombotic drugs, more over in case of primary
percutaneous coronary intervention (PCI). Use of Glycoprotein IIb/IIIa inhi-
bitors (GPI) remains debatable, level of guidelines has been modified in the
successing edition of guidelines. In the latest ESC guidelines, GPI may be
considered in high risk patients undergoing transfer for primary PCI, angio-
graphic evidence of massive thrombus, slow or no-reflow or thrombotic
complication. In front of the varying recommendations, we decided to analyze
clinical characteristics of patients with STEMI according to the use of GPI.
We evaluate complications during hospitalization, particularly bleeding
events. A follow up at 6 months was performed analyzing major cardio-
vascular, myocardial function and bleedings events. The cost of patient's
management was also analyzed.
From January 2010 to December 2012, 393 patients with STEMI were
treated by primary PCI at Lariboisière hospital. To compare patients with or
without administration of GPI we used database angiography. Different data
were collected: risk factors, medical history, STEMI characteristics at admis-
sion, complications post procedure, management delay, anticoagulant/anti-
platelet treatment during angioplasty and duration of hospitalization. Left
ventricular ejection fraction was evaluated on day 4 and 6 months. Data at
6 months were collected: ischemic complications, bleeding events, stroke,
ACS and death. Analysis of patient's management cost was evaluated through
PCI, hospitalization per day, transfusion, GPI’s administration, use of bivali-
rudin and antiplatelet medication. Total cost for each patient was calculated. 
This study carried out an evaluation of clinical practice, combined with
cost/efficacy analysis.
042
Gender-related differences in therapeutic and outcomes in patients
with non-ST-segment elevation myocardial infarction
Sylvain Carillo, Frédéric Moulin, Frédéric Benzakin, Simon Lemoine,
Etienne Aliot, Zied Frikha, Michael Angioi
CHU Nancy, Département de Cardiologie, Vandoeuvre Les Nancy, France
Introduction: According to previous study, there are significant differen-
cies between men and women in epidemiology, diagnosis, treatment and prog-
nosis of coronary artery disease.
Objectives: This study examines the impact of gender difference in clin-
ical course, therapeutic approach and outcomes in non-ST-segment elevation
myocardial infarction (NSTEMI) patients. 
Methods: A retrospective monocentric study enrolling 596 subsequent
patients (168 women and 428 men) hospitalized for NSTEMI in the Cardiac
Care Unit, between January 2006 and June 2008.
Results: Women were older than men (69.2±13.1 vs 62.1±13.3;
p<0.0001). There was higher prevalence of hypertension in women (68.5% vs
57%; p=0.001), while active smoking was higher in men (34.7% vs 18.5%;
p=0.0001). There was no difference in clinical presentation between genders.
Only the GRACE score > 140 was significantly higher in women than in men
(50% vs 30%; p<0.0001).Although women underwent coronary angiography
similar to men (86.9% vs 91.8%; p=0.066), the prevalence of revascularization
was significantly higher in men (75.5% vs 63.7%; p=0.015). At 30 days, there
were no difference in MACE between genders (10.7% in women vs 7.2%;
p=ns). After a mean follow-up of 37±15.4 months, cardiac death, myocardial
infarction and MACE were significantly higher in women (20.8% vs 9%,
p<0.0001; 27.7% vs 19.2%, p=0.026; 44% vs 29.3%, p=0.005, respectively).
On multivariate analysis, gender was strongly predictive of MACE (p=0.02).
© Elsevier Masson SAS. All rights reserved.
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Conclusions: Although thirty days follow-up was similar between men
and women, long term follow-up in patients presenting with NSTEMI demon-
strated a significant worst prognosis in female.
043
Left atrial echographic parameters predict silent atrial fibrillation
after myocardial infarction 
Karim Stamboul (1), Vanessa Fernandez (1), Aurélie Gudjoncik (1), Luc
Lorgis (1), Jean-Claude Beer (1), Claude Touzery (1), Marianne Zeller (2),
Yves Cottin (1)
(1) CHU Bocage, Cardiologie, Dijon, France – (2) INSERM U866,
LPPCM, Faculté de Médecine, Dijon, France
Background::Silent AF has been suggested to be common in AMI. 
Objectives: The aims of our study were to assess silent AF incidence after
AMI and determine its predictive factors, including left atrium parameters.
Methods: 849 consecutive AMI were prospectively analyzed by contin-
uous ECG monitoring (CEM) during the first 48 hours after admission. Silent
AF was defined as at least 1 episode > 30 sec without p waves, and with irreg-
ular RR intervals. Symptomatic AF was defined as symptomatic episodes of
AF that lasted ≥12hours. 
Results: One hundred and thirty five patients (16%) developed silent AF
and 45 (25%) had symptomatic AF. Compared with the no AF group, patients
with silent AF were markedly older (mean age 80 (67-85) vs. 62 (53-75) y,
p<0.001), more frequently women (43% vs. 30%, p=0.006), and less smoker
(20% vs 36%, p<0.001). An elevated CRP (>3 mg/L) were gradually more
frequent across the 3 groups (62%, 73%, and 82%, p=0.003). Patients with
silent AF also had significant left atrial (LA) enlargement, with indexed LA
surface at 10.79 (8.61-12.58) vs. 9.30 (7.54-11.04)cm²/m²; p<0.001 and
indexed LA volume at 29.50 (21.30-44.05) vs. 24.45 (18.25-33.15)cm3/m²;
with p<0.001. By multivariate analysis, age, history of AF, indexed LA sur-
face, and LVEF were identified as independent explanatory variables for
occurrence of silent AF. The same variables, in addition to hypertension and
heart rate, were associated with the development of symptomatic AF. By ROC
curve analysis, an indexed LA surface at 10.8 cm²/m² was identified as the
best predicting value for silent AF, with a sensibility at 50% and specificity at
72%. For symptomatic AF, an indexed LA surface at 11.5 cm²/m² was the best
threshold, with a sensibility at 50%, and specificity at 81%.
Conclusion: Silent AF is very common after AMI and share similar char-
acteristics with symptomatic AF, including older age, history of AF, altered
LVEF and LA enlargement. Our data strongly suggest gradual severity of the
disease.
044
Antiplatelet treatment and bleeding complications in diabetic patients
after des implantation
Panagiotis Karyofyllis, Constantinos Doulaptsis, Ioannis Moukas, Sophia
Thomopoulou, Vassilis Voudris 
Onassis Cardiac Surgery Centre, Athens, Grèce
Purpose: Dual antiplatelet treatment (DAPLT) for at least 12 months is
recommended after drug eluting stent (DES) implantation. We investigate the
frequency, correlates, and clinical significance of bleeding in diabetic patients
(pts) after 1st generation DES implantation and long-term DAPLT. 
Methods: We assessed 610 consecutive DM pts (male 80%, mean age
65±9 years) treated with 1st generation DES (80% sirolimus eluting, 10%
paclitaxel eluting, 10% combined). Five years clinical follow-up (FU),
obtained in 587/610 (96%) of them. Bleeding complications were defined
according to ARC definitions. Death, myocardial infarction, cerebrovascular
accident and their combination were defined as cardiovascular adverse events. 
Results: The incidence of bleeding was higher in DAPLT pts (14.9% vs
4.3%, p < 0.001). DAPLT was associated with higher incidence of type 1 and
2 bleeding (8.2% vs 1.9%, p=0.002 and 3.7% vs 0.5%, p=0.014, respectively),
whereas there was no effect on type 3 (2.9% vs 1.9%, p=ns) . Cardiovascular
adverse events were not more frequent observed in pts with bleeding as com-
pared with those without bleeding. In a multivariable analysis, smoking and
DAPLT was an independent predictor for overall bleeding (HR 1.89, 95% CI
1.086-3.286, p=0.024 and HR 3.82, 95% CI 1.89-7.728, p< 0.001 respec-
tively). Smoking was also predictor for type 3 bleeding (HR 9.026, 95% CI
1.187-68.644, p=0.034). 
Conclusion: Long-term DAPLT in diabetic pts treated with DES is asso-
ciated with higher risk of overall and type 1 and 2 bleeding. Smoking was pre-
dictor for overall and type 3 bleeding according to ARC definitions.
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Angiopoietin-like 4 serum levels on admission for acute myocardial
infarction are associated with no-reflow assessed by magnetic reso-
nance imaging
Claire Bouleti (1), Thomas Mathivet (2), Jean-Michel Serfaty (3), Philippe
Cluzel (4), Gabriel Steg (3), Gilles Montalescot (4), Stephane Germain (2)
(1) Hôpital Bichat-Claude Bernard, Cardiologie, Paris, France – (2) Col-
lège de France-CIRB- INSERM 1050, Paris, France – (3) Hôpital Bichat-
Claude Bernard, Paris, France – (4) Hôpital de la Pitié-Salpêtrière,
Paris, France
Background: No-reflow in ST-segment elevation acute myocardial infarc-
tion (STEMI) is associated with a poor clinical prognosis. Its pathophysiologal
mechanisms are not totally elucidated yet but enhanced vascular permeability
plays a key role in this process. ANGPTL4 has been implicated in vascular
permeability in experimental models of AMI. We therefore sought to investi-
gate whether baseline ANGPTL4 serum levels are associated with no-reflow
after primary percutaneous coronary intervention (PPCI). 
Methods: A group of 41 consecutive patients with a first STEMI, under-
going successful PPCI within 12h of onset of symptoms were enrolled. Blood
samples were obtained from all patients on admission for ANGPTL4 levels
measurement. No-reflow was assessed by cardiac magnetic resonance imaging
(MRI), the reference method. 
Results: MRI-detected no-reflow was observed in 20 patients (48.8%).
Variables independently associated with no-reflow at multivariate logistic
regression analysis were: lower ANGPTL4 plasma levels (odds ratio 0.82,
95% CI 0.70-0.98, P=0.02), higher troponin T peak (odds ratio 1.03, 95% CI
1.00-1.05, P=0.03), higher incidence of left anterior descending coronary
artery (LAD) as culprit artery (odds ratio 14.61, 95% CI 1.24-172.49, P=0.03),
and higher C-reactive protein levels (odds ratio 1.18, 95% CI 1.00-1.39,
P=0.05). 
Conclusion: ANGPTL4 serum levels predict MRI-detected no-reflow after
successful PPCI in STEMI patients. Given the recently demonstrated therapeutic
role of ANGPTL4 in diminishing no-reflow and therefore infarct size in pre-clin-
ical animal models, these findings in humans may open new fields of research. 
046
Patient and worker radiation protection optimization strategy for
interventional cardiology
Guillaume Bonniaud (1), Emmanuel Burguin (1), Alain Kermarrec (2),
Christophe Le Ray (2), Emmanuelle Filippi (2)
(1) Centre Hospitalier Bretagne Atlantique, Imagerie Médicale, Vannes,
France – (2) Centre Hospitalier Bretagne Atlantique, Cardiologie, Vannes,
France
Objective: The purpose of this work was to implement an optimization
strategy for both worker and patient radiation protection for coronarography
and angioplasty procedures in Centre Hospitalier Bretagne Atlantique
(CHBA). It was embedded in professionnal practices assessment programs
required by French health regulatory (EPP). 
Material and Methods: The Deming cycle type method developed is based
on CIRSE and SIR radiation protection guidelines. It was implemented in
4 steps (S1 to S4). S1: Local practices analysis. S2: Definition and evaluation
of dose metrics for patient (Peak Skin Dose – PSD [mGy], Kerma-Air Product
– KAP [Gy.cm²]) and workers (Effective Dose per month – ED [μSv/month]).
S3: Comparison between local practices and reference levels (Ray-Act study,
© Elsevier Masson SAS. All rights reserved.
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2010 for KAP and Vano et al. 2006 for ED), choice of optimization issues for
S4. S4: Optimization work based on medical and scientific literature databases. 
Results: Metrics have been extracted from 2431 procedures for patient (April
2011 to December 2012) and from 1852 procedures for workers (January 2012 to
April 2013) before and after first optimization step respectively (see table). In
terms of patient radiation protection, S3 as shown local levels 60% lower than
reference levels. Optimization based on x-ray system features adjustment has
allowed to further decrease that level of 10%. Moreover, a method to estimate
DPP after procedure, using DICOM Dose Report was established. It allows iden-
tification of patients who overstep significant CIRSE-SIR PSD threshold to offer
them a specific follow-up. In terms of workers radiation protection, S3 has shown
heterogeneous ED local levels from 36 to 90% lower than reference level. Opti-
mization step S4 has narrowed ED from 53 to 90%. 
Conclusion: The strategy implemented has allowed to optimized significantly
both patient and worker radiation protection practices. Evaluation will be carried
out twice a year to keep CHBA practices at their current levels (table above).
047
Impact on early complications of non-compliance with guidelines-
recommended timelines for reperfusion therapy in STEMI patients.
The FAST-MI 2010 registry
Etienne Puymirat (1), Luc Lorgis (2), Pierre Coste (3), Sandrine Charpen-
tier (4), Gilles Lemesle (5), Eric Durand (1), Vincent Bataille (4), Tabassome
Simon (6), Nicolas Danchin (1)
(1) Hôpital Européen Georges Pompidou (HEGP), Cardiologie, Paris,
France – (2) CHU Dijon, Cardiologie, Dijon, France – (3) Hôpital Haut-
Lévèque, Cardiologie (USIC), Pessac, France – (4) CHU Rangueil, Tou-
louse, France – (5) CHRU de Lille, Lille, France – (6) Hôpital Saint
Antoine, Cardiologie, Paris, France
Background: In STEMI patients, the ESC 2008 guidelines recommend a
time from qualifying ECG to PCI (T-ECG-PCI) <90 minutes for patients with
symptom onset <120 minutes, and <120 minutes when symptom onset is
>120 minutes. Likewise fibrinolysis should be administered <30 minutes from
ECG (T-ECG-lysis).
Aim: To assess in-hospital outcomes in patients with fibrinolysis or pri-
mary PCI (PPCI) according to the recommended times to reperfusion therapy.
Methods: FAST-MI 2010 is a nationwide French registry that included
4169 patients with AMI at the end of 2010. Of those, 1706 had STEMI and were
referred for intended PPCI (n=1376), or had IV fibrinolysis (n=330). Patients were
divided in 4 groups: Gr1 (T-ECG-PCI <90 min if onset <120 min or <120 min if
time from onset >120 min; n=711), Gr2 (T-ECG-PCI > 90 min if symptom onset
<120 min or T-ECG-PCI > 120 min if symptom onset > 120 min; n=665), Gr3
(T-ECG- lysis ≤ 30 min, n=222), and Gr4 (T-ECG-lysis > 30 min, n=108).
Results: Overall, patients with intended PPCI were older than patients treated
with fibrinolysis, and those meeting guidelines requirements were younger than
those not meeting these requirements. GRACE score was higher in Gr2 than in
Gr1, and lytic-treated patients had lower GRACE scores. In-hospital mortality was
3.5% in Gr2, vs 1.1% in Gr1 and 1.8% in patients with fibrinolysis. After adjust-
ment for confounders, not meeting the recommended timelines for PPCI was asso-
ciated with a nearly 3-fold increase in hospital mortality (OR: 2.92; 95%CI:1.17-
7.30, P=0.02). In fibrinolytic-treated patients, timely administration of lysis was
associated with a lower hospital death rate (1.4% vs 2.8%), though the difference
was not statistically significant.
Conclusion: These real-world data confirm the importance of a short time
delay between qualifying ECG and reperfusion therapy in STEMI patients 
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Delay to reperfusion in acute ST-elevation myocardial infarction:
guidelines versus real-life practice in the RESURCOR registry
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(1) Cardiologie, Annecy, France – (2) Hôpital, RENAU, Annecy, France
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Background: Rapid reperfusion is crucial in the treatment of acute ST-ele-
vation myocardial infarction (STEMI). The latest STEMI guidelines from the
European Society of Cardiology (ESC) recommend primary percutaneous cor-
onary intervention (PPCI) if the delay between first medial contact (FMC) and
wire passage is ≤120 min and fibrinolysis for delays >120 min. With a ≤20 min
delay from FMC to wire acceptable for PPCI, it appears that most patients
would be eligible for/have access to PPCI. We sought to assess time to reperfu-
sion in STEMI patients in a real-life registry and according to ESC guidelines.
Methods: RESURCOR is an ongoing registry of all cases of acute STEMI
in the north French Alps, an area that covers three French departments (Isere,
Savoie, Haute-Savoie), with 1.8 million inhabitants, and a population that dou-
bles during the summer and winter holidays. In RESURCOR, delays and care
pathway for STEMI patients, from symptoms onset to reperfusion, were
recorded by the physicians. 
Results: Between October 2002 and December 2011, 6169 patients were
enrolled in the RESURCOR registry. Of these, 2573 patients were treated with
PPCI and had data recorded for delay from FMC to artery puncture;
329 patients had a contraindication to fibrinolysis and 556/2244 (25%) of the
PPCI patients without a contraindication to fibrinolysis had a delay from
FMC-to-artery puncture >120 min. A total of 2768 patients were treated with
fibrinolysis with recorded delays and 1381/2768 (50%) were admitted to a
PCI-capable hospital with a delay from FMC-to-admission (or artery puncture
in case of urgent coronary angiogram) <120 min. 
Conclusion: When the latest ESC STEMI guidelines are applied to a real-
world population, it appears that one-quarter of patients treated with PPCI
would have been recommended for fibrinolysis and half of those who received
fibrinolysis would have been recommended for PPCI.
Abstract 046 – Table. Optimization steps of radiation protection
Reference level Local level CHBA 1 Ratio vs Reference Local level CHBA 2 
after optimization
Ratio vs Loval 
level CHBA 1
Patient radiation 
protection
Metric PKA [Gy-cm2] 
Ray-Act 2010
PKA [Gy-cm2] 
04/2011 to 02/2012
[%] PKA [Gy-cm2] 03/2012 
to 12/2012
[%]
Coronarography 
(Number of procedures)
56 (31167) 27 (779) –53% 24 (683) –10%
Angioplasty 
(Number of procedures)
110 (25356) 38 (99) –68% 35 (91) –10%
Worker radiation 
protection
Metric ED [μSv/month] 
Vano et al. 2006
ED [μSv/month] 
10/2012 to 04/2013
[%]
Cardiologist 1
120
77 –36% 56 –27%
Cardiologist 2 12 –90% 13 8%
Cardiologist 3 17 –86% 13 –24%
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Background: Rescue percutaneous coronary intervention (PCI) is associ-
ated with improved clinical outcomes for ST-segment myocardial infarction
(STEMI) patients after failed fibrinolysis therapy. Hyperglycemia on admis-
sion has been shown to be a powerful predictor of mortality after acute MI,
particularly in non-diabetic patients. The aim of our study was to assess the
predictive value of admission glucose levels on long-term mortality in patients
with rescue PCI.
Patients and Methods: From the obseRvatoire des Infarctus de Côte d’Or
(RICO) survey, 510 consecutive non-diabetic STEMI patients admitted to the
intensive care unit for rescue PCI after failed fibrinolysis therapy were
included in the study. We analyzed one-year cardiovascular mortality. Rescue
PCI was deemed necessary in patients with ST-segment resolution <50%
90 minutes after lysis, or a Thrombolysis In Myocardial Infarction (TIMI) per-
fusion grade in the infarct-related artery <3 at the time of angiography in
patients with persisting equivocal symptoms. Patients were classified according to
admission glycemia: <11 mmol/L (group I, n=452) and ≥11 mmol/L (group II,
n=58).
Results: One-year cardiovascular (CV) mortality was 6% in group I and 29%
in group II (p<0.001). Patients with hyperglycemia on admission were more likely
to develop cardiogenic shock (43% vs. 10%, p<0.001) and to have higher peak
CPK (4052(2465-6283) vs. 2667 (1303-4865), p=0.007), reflecting a bigger
infarct size than the others, although the revascularization results were similar. 
By multivariate analysis, glycemia on admission ≥11 mmol/L (odds ratio
6.380, 95% confidence interval 2.075 to 19.617, p=0.001) and GRACE risk
score (OR: 1.027, 95% CI 1.012-1.042, p<0,001) were independently associ-
ated with 1-year CV mortality
Conclusion: In non-diabetic patients undergoing rescue PCI after failed
fibrinolysis, glycemia on admission is a predictive factor for long-term CV
survival. This study suggests that evaluating early glycemic control may be
useful in the setting of rescue PCI.
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nosis among coronary artery Tunisian patients at high-risk according
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Introduction: The incidence of signiﬁcant carotid artery disease (CAS) in
patients scheduled for myocardial revascularization depends on age, cardio-
vascular risk factors, and the screening method. All previous studies agree that
this combination was associated with an adverse prognosis. Stroke is frequent
in patients with coronary artery disease (CAD), accounting for at least one-
fourth of all cardiovascular events during the follow-up. However, the mean
prevalence of CAS > 60% in patients with CAD is 9%, too low to justify
routine carotid screening. The European Society of Cardiology (ESC) Guide-
lines for carotid artery screening before myocardial revascularization are
recently proposed.
Objectives: To evaluate, in our country, the usefulness of the screening
criteria recommended by the ESC 2010 Guidelines on myocardial revascu-
larization for patients classified as being at high risk of asymptomatic severe
CAS and to study the impact of this presence on the short and long-term prog-
nosis. 
Patients and methods: We performed a retrospective analysis of pros-
pectively collected data obtained from 155 CAD patients (mean age
64.5±10.3 years, 77.4% were male) admitted in our center between 2010
and 2012. Each patient underwent a coronary angiography then carotid
Doppler studies. According to the recent ESC guideline on screening for
CAS prior myocardial revascularization, we have considered being high-
risk individuals:  Patients >75 year-old, with a history of stroke or tran-
sient ischemic accident (TIA), with peripheral artery disease (PAD), and those
with left main disease and 3-vessels disease. We have followed our patients
and reported the occurrence of major adverse cardiac and cerebro-vascular
events (MACCE) including stroke, ischemic recurrence, revascularization,
and cardiac death. 
Results: In the studied population, 21.3% had a significant CAS (diameter
stenosis >70%). In the subgroup analysis, this prevalence was higher in CAD
patients with previous ischemic stroke or TIA (38.1%) and in those with
peripheral artery disease (33.3%) than in patients with left main stenosis
(15.5%). 
The MACCE rate during the mean follow up period of 12.5±6.8 months was
40%. The incidence of MACCE was significantly higher in pts with a significant
CAS (48% vs 32.5% in patients without CAS (<20% stenosis); p=0.049). It was
mainly due to a significant increase of ischemic stroke (6.7% vs 0%; p=0.019) and
to more cardiac ischemic recurrence (42.7% vs 27.5%; p=0.048).
Conclusions: The prevalence of significant CAS was high enough to jus-
tify a routine screening in this high risk selected population of Tunisian CAD
especially for those with PAD and prior stroke. The presence of severe CAS
was significantly associated with the occurrence of MACCE in these patients.
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ding risk scores with the bleeding events among Tunisian patients
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Background: Bleeding is a major complication in patients treated for acute
coronary syndromes (ACS) with antithrombotic and invasive therapies.
Consequently, the benefit of such therapies should be balanced against the
potential risk of hemorrhagic complications. CRUSADE and more recently
MEHRAN models provide two risk scores that predict the likelihood of major
bleeding in patients hospitalized with ACS.
The aim of this study: was to evaluate the performance of CRUSADE
AND MEHRAN risk scores to predict in-hospital major bleeding in a contem-
porary cohort of patients hospitalized for ACS in Tunisia.
Methods and results: The study subjects were 278 consecutive
patients admitted to our center between January 2010 and August 2011
with ACS. For each patient, we calculated both the CRUSADE and
MEHRAN risk score and evaluated its discrimination by the C statistic. By
CRUSADE and MEHRAN risk scores, our patients were classified as high
or very high risk of major bleeding in 24.8%, 45.7% of cases, respectively.
The overall incidence of in-hospital bleeding events and major bleeding
(BARC major definition: BARC 3, BARC 4 and BARC 5) was 12.6%,
4.4%, respectively. The major bleeding rate increased with the CRUSADE
risk category: very low 2.3%; low 3%; moderate 3.6%; high 8.1%; and
very high 9.4%.There were twice fewer observed major hemorrhagic
events than predict in case of high and very high risk according to CRU-
SADE score. A stepwise increase in rates of major bleeding with
increasing MEHRAN score was also noted (low 0%, moderate 4.9%, high
4.4% vs very high 10.2%). The incidence of the major bleeding predicted
by MEHRAN is rather close to that observed in our population. The curve
ROC showed a better correlation of the MEHRAN score (area under the
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curve 0.76) than the Crusade score (area under the curve 0.67) with the
hemorrhagic events.
Conclusions: In routine clinical practice, bleeding is a relatively frequent
non-cardiac complication of contemporary therapy for ACS. These two scores
discriminate major bleeding risk. The MEHRAN score seems more correlated
to the real life of the Tunisian coronary patients.*
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Clopidogrel crushed is not superior to whole tablet in diabetic patients
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Background: Pharmacodynamic studies have shown that persistently high
residual platelet reactivity (HRPP) is common in patients with diabetes in
spite of clopidogrel treatment. Even, a 600-mg clopidogrel loading dose is not
sufﬁcient to overcome this effect, especially in diabetic patients with ACS.
This can be explained by altered resorption, altered liver metabolism, or
altered platelet response. Recently, it was demonstrated that clopidogrel given
crushed provided faster absorption and greater rate of clopidogrel inactive
metabolite in healthy subjects. 
Objective: The hypothesis of the study was that 600 mg clopidogrel
loading dose (LD) administered crushed may provide more effective platelet
inhibition than an equal clopidogrel dose taken orally as whole tablets in
patients with type 2 diabetes mellitus presenting with ACS.
Methods: In a prospective, single-center, single-blind study, 30 (58.9±8.4
years; 17 males) ACS diabetic patients were randomized to either 600 mg crushed
clopidogrel (n=15) or whole tablets (n=15) follow by a maintenance dose of 150
mg, respectively. Pharmacodynamic assessment was performed by VerifyNow
P2Y12 system accumetrics at 24 h and 3 days post LD. High Residual platelet
reactivity (HRPR) was defined as platelet reactivity units (PRU) > 235.
Results: The baseline characteristics were no different in the two groups. We
noted no difference between the antiplatelet effect produced by 600 mg crushed
clopidogrel compared with whole tablets at both 24h (PRU=199.73±79.3 vs
216.9±70.1; p=0.53) and at 3 days (PRU=164.3±92.9 for crushed clopidogrel vs
160.5±73.5 for whole tablet; p=0, 9). HRPR rate also was similar in the two
groups, 40% (p=1) at 24h and diminished significantly in both groups at 3 days to
20% of patients (p<0,001).
Conclusions: Despite the small sample size, the present study demon-
strates that clopidogrel given crushed in diabetic ACS patients is as effective
as whole tablet
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Background: The five years results of the LEADERS trial demonstrated
that the relative risk of MACE was 17% lower with BioMatrix Flex vs.
Cypher Select and the BES was also associated with a significant 74% reduc-
tion in definite VLST. BioMatrix Flex is superior to Cypher stent in
subgroups of patients at higher risk (High Syntax score, Patients with STEMI,
Bifurcation lesions). Are these good results confirmed in the “real word”?
Objectives: The purpose of the present observational study is to capture
the clinical events of patients receiving the CE marked BioMatrix™ and the
BioMatrix Flex™ stents.
Methods: Prospective, multi-center observational study conducted in 2537
all-comer consecutive patients with symptomatic CAD in 40 French centers.
The primary endpoint is the occurrence of major adverse cardiac and cere-
brovascular events (MACCE), defined as composite of cardiac death, myocar-
dial infarction (Q-wave and non-Q-wave), cerebrovascular events and
clinically indicated target vessel revascularization at 12 months. 
Results: Population consisted of 76% of males, mean age: 65.67± 11.2 yrs.
Indications were 32.80% stable angina, 32.85% ACS and 19.73% silent isch-
emia; 41.10% of patients had multivessel disease. Risk factors were: hyperten-
sion (64.80%), dyslipidemia ( 68.43%), diabetes I & II (34.63%), family
history (30.26%) and current smoker (22.68%). 
Procedural results: Patients had 1.12±0.32 procedures and mean number
of stents implanted per procedure was 1.11±0.36. Procedural success was
obtained in 99.47%.
In-hospital results: 16 patients (0.63%) experienced at least one MACCE
in hospital including 5 deaths (0.20%) 3 MI (0.12%), no emergency CABG,
9 repeat PCI (0.35%) and 4 (0.16%) stent thrombosis.
Conclusion: In a real-life, post market registry in France, the BioMatrix™
and BioMatrix Flex™ confirm the excellent outcome observed in the Leaders
trial, one year MACCE (primary endpoint) will be available at the moment of
the presentation.
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Purpose: Despite restoration of TIMI 3 flow in the infarct-related artery
during pPCI, about 30% of patients experience incomplete myocardial reper-
fusion due to microvascular obstruction. Incomplete ST-segment resolution
hours after PCI is associated with increased risk of major adverse events.
Immediate stenting (IS) could lead to increase distal embolization and micro-
vascular obstruction, altering myocardial perfusion. The aim of this study was
to compare delayed stenting (DS) with IS in pPCI. 
Methods: We prospectively collected data from 180 consecutive patients
admitted with STEMI of <12 h duration undergoing pPCI with indication of
stent implantation. The decision to perform IS (n=127) or DS (n=53) was left
to the operators. In the IS group, stent placement was done immediately
during pPCI; in the DS group, after restoration of TIMI 3 flow patients were
given antithrombotic therapy and had a stent implanted several days later. The
primary endpoint was ST-segment resolution (STR) measured on ECGs 1 h
after pPCI; secondary endpoints were postprocedure TIMI flow and in-
hospital culprit artery reocclusion rate. Propensity score were used in regres-
sion adjustment to reduce bias between groups. 
Results: 96.2% of the DS patients had second angiography 4.3±2 days
after the pPCI. A stent was implanted in all patients in the IS group vs 45.1%
in the DS group (p<0.001). 75% STR was found in 13.4% in the IS group vs
37.7% in the DS group (propensity-score-adjusted OR 3.7, 95%CI 1.5-8.8,
p=0.004). TIMI 3 flow restoration was obtained in 92.1% in the IS group vs
98.1% in the DS group at the end of the pPCI (OR=0.97, 95%CI 0.2-4.4). In
hospital documented infarct related artery reocclusion was 5.5% vs 1.9%
(OR=0.21, 95%CI 0.02-2.14).
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